The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Drug–Target Kinetics in Drug Discovery
Open accessAbstract
The development of therapies for the treatment of neurological cancer faces a number of major challenges including the synthesis of small molecule agents that can penetrate the blood-brain barrier (BBB). Given the likelihood that in many cases drug exposure will be lower in the CNS than in systemic circulation, it follows that strategies should be employed that can sustain target engagement at low drug concentration. Time dependent target occupancy is a function of both the drug and target concentration as well as the thermodynamic and kinetic parameters that describe the binding reaction coordinate, and sustained target occupancy can be achieved through structural modifications that increase target (re)binding and/or that decrease the rate of drug dissociation. The discovery and deployment of compounds with optimized kinetic effects requires information on the structure-kinetic relationships that modulate the kinetics of binding, and the molecular factors that control the translation of drug-target kinetics to time-dependent drug activity in the disease state. This Review first introduces the potential benefits of drug-target kinetics, such as the ability to delineate both thermodynamic and kinetic selectivity, and then describes factors, such as target vulnerability, that impact the utility of kinetic selectivity. The Review concludes with a description of a mechanistic PK/PD model that integrates drug-target kinetics into predictions of drug activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122
The Behavior and Significance of Slow‐Binding Enzyme Inhibitors
Morrison, J. F., & Walsh, C. T. (1988) · Advances in Enzymology - and Related Areas of Molecular Biology · doi:10.1002/9780470123072.ch5 · Cited by 840
Clinical biomarkers in drug discovery and development
Frank, R., & Hargreaves, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1130 · Cited by 794
The drug–target residence time model: a 10-year retrospective
Copeland, R. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.18 · Cited by 722
Global Kinetic Explorer: A new computer program for dynamic simulation and fitting of kinetic data
Johnson, K. A., Simpson, Z. B., & Blom, T. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2008.12.024 · Cited by 595
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
NanoBRET—A Novel BRET Platform for the Analysis of Protein–Protein Interactions
Machleidt, T., Woodroofe, C. C., Schwinn, M. K., Méndez, J., Robers, M. B., Zimmerman, K., Otto, P., Daniels, D. L., Kirkland, T. A., & Wood, K. V. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00143 · Cited by 491
Drug–target residence time: critical information for lead optimization
Lu, H., & Tonge, P. J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.176 · Cited by 432
Self-citationLauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490706 · Cited by 429
Prolonged and tunable residence time using reversible covalent kinase inhibitors
Bradshaw, J. M., McFarland, J. M., Paavilainen, V. O., Bisconte, A., Tam, D., Phan, V. T., Romanov, S., Finkle, D., Shu, J., Patel, V., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1817 · Cited by 422
Biochemical mechanisms of drug action: what does it take for success?
Swinney, D. C. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1500 · Cited by 394
FitSpace Explorer: An algorithm to evaluate multidimensional parameter space in fitting kinetic data
Johnson, K. A., Simpson, Z. B., & Blom, T. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2008.12.025 · Cited by 344
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis
Di Paolo, J. A., Huang, T., Balazs, M., Barbosa, J., Barck, K. H., Bravo, B. J., Carano, R. A. D., Darrow, J., Davies, D. R., DeForge, L. E., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.481 · Cited by 340
Pharmacologic target-mediated drug disposition
Levy, G. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.134 · Cited by 332
Rawat, R., Whitty, A., & Tonge, P. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2235848100 · Cited by 330
Self-citationPostantibiotic Suppression of Bacterial Growth
Bundtzen, R. W., Gerber, A. U., Cohn, D. L., & Craig, W. A. (1981) · Clinical Infectious Diseases · doi:10.1093/clinids/3.1.28 · Cited by 311
Long‐lasting target binding and rebinding as mechanisms to prolong in vivo drug action
Vauquelin, G., & Charlton, S. J. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00936.x · Cited by 298
Target-mediated drug disposition and dynamics
Mager, D. E. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.041 · Cited by 244
A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics
Chaikuad, A., M C Tacconi, E., Zimmer, J., Liang, Y., Gray, N. S., Tarsounas, M., & Knapp, S. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1629 · Cited by 242
Kinetics for Drug Discovery: an industry-driven effort to target drug residence time
Schuetz, D. A., de Witte, W. E. A., Wong, Y. C., Knasmueller, B., Richter, L., Kokh, D. B., Sadiq, S. K., Bosma, R., Nederpelt, I., Heitman, L. H., et al. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.02.002 · Cited by 226
Enzymatic Transition States, Transition-State Analogs, Dynamics, Thermodynamics, and Lifetimes
Schramm, V. L. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061809-100742 · Cited by 225
Evans, E. K., Tester, R., Aslanian, S., Karp, R., Sheets, M., Labenski, M. T., Witowski, S. R., Lounsbury, H., Chaturvedi, P., Mazdiyasni, H., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203489 · Cited by 220
Copeland, R. A. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003677725 · Cited by 209
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics
Blair, J. A., Rauh, D., Kung, C., Yun, C.-H., Fan, Q.-W., Rode, H., Zhang, C., Eck, M. J., Weiss, W. A., & Shokat, K. M. (2007) · Nature Chemical Biology · doi:10.1038/nchembio866 · Cited by 202
Conformational Adaptation in Drug–Target Interactions and Residence Time
Copeland, R. A. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.112 · Cited by 196
Target–drug interactions: first principles and their application to drug discovery
Núñez, S., Venhorst, J., & Kruse, C. G. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.013 · Cited by 181
Luckner, S. R., Liu, N., am Ende, C. W., Tonge, P. J., & Kisker, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.090373 · Cited by 174
Self-citationZeng, Q., Wang, J., Cheng, Z., Chen, K., Johnström, P., Varnäs, K., Li, D. Y., Yang, Z. F., & Zhang, X. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01073 · Cited by 161
Depletion of antibiotic targets has widely varying effects on growth
Wei, J.-R., Krishnamoorthy, V., Murphy, K. C., Kim, J.-H., Schnappinger, D., Alber, T., Sassetti, C. M., Rhee, K. Y., & Rubin, E. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018301108 · Cited by 159
Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer
Heffron, T. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00618 · Cited by 151
Translating slow-binding inhibition kinetics into cellular and in vivo effects
Walkup, G. K., You, Z., Ross, P. L., Allen, E. K. H., Daryaee, F., Hale, M. R., O’Donnell, J. C., Ehmann, D. E., Schuck, V., Buurman, E. T., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1796 · Cited by 148
Self-citationBasavapathruni, A., Jin, L., Daigle, S. R., Majer, C. R., Therkelsen, C. A., Wigle, T. J., Kuntz, K. W., Chesworth, R., Pollock, R. M., Scott, M. P., et al. (2012) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12050 · Cited by 147
Strategic Approach to Fit-for-Purpose Biomarkers in Drug Development
Wagner, J. A. (2007) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094611 · Cited by 143
Structure–kinetic relationship study of CDK8/CycC specific compounds
Schneider, E., Böttcher, J., Huber, R., Maskos, K., & Neumann, L. (2013) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1305378110 · Cited by 129
Lewandowicz, A., Tyler, P. C., Evans, G. B., Furneaux, R. H., & Schramm, V. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300259200 · Cited by 126
Sykes, D. A., Dowling, M. R., Leighton-Davies, J. R., Kent, T. C., Fawcett, L., Renard, E., Trifilieff, A., & Charlton, S. J. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.194456 · Cited by 122
In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant
de Witte, W. E. A., Danhof, M., van der Graaf, P. H., & de Lange, E. C. M. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.06.008 · Cited by 121
Lu, H., England, K., Ende, C. W. A., Truglio, J. J., Luckner, S. R., Reddy, B. G., Marlenee, N. L., Knudson, S. E., Knudson, D. L., Bowen, R. A., et al. (2009) · ACS Chemical Biology · doi:10.1021/cb800306y · Cited by 113
Self-citationDiscovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR
Heffron, T. P., Ndubaku, C. O., Salphati, L., Alicke, B., Cheong, J., Drobnick, J., Edgar, K. A., Gould, S. E., Lee, L. B., Lesnick, J., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00005 · Cited by 113
Type II Inhibitors Targeting CDK2
Alexander, L. T., Möbitz, H., Drueckes, P., Savitsky, P. A., Fedorov, O., Elkins, J. M., Deane, C. M., Cowan‐Jacob, S. W., & Knapp, S. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00398 · Cited by 103
The importance of drug-target residence time.
Zhang, R., & Monsma, F. J. (2009) · PubMed · Cited by 102
Target Engagement in Lead Generation
Durham, T. B., & Blanco, M.-J. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.12.076 · Cited by 100
Swinney, D. C. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776743093 · Cited by 97
Plasma and Cerebrospinal Fluid Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420
Broniscer, A., Panetta, J. C., O'Shaughnessy, M. A., Fraga, C. H., Bai, F., Krasin, M. J., Gajjar, A. J., & Stewart, C. F. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2372 · Cited by 95
Tautermann, C. S., Kiechle, T., Seeliger, D., Diehl, S., Wex, E., Banholzer, R., Gantner, F., Pieper, M. P., & Casarosa, P. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401219y · Cited by 94
Robak, T., & Robak, E. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.685650 · Cited by 88
Immunopathologic role of B lymphocytes in rheumatoid arthritis: Rationale of B cell-directed therapy
Martinez‐Gamboa, L., Brezinschek, H. P., Burmester, G. R., & Dörner, T. (2006) · Autoimmunity Reviews · doi:10.1016/j.autrev.2006.02.004 · Cited by 83
Ayaz, P., Andres, D., Kwiatkowski, D., Kolbe, C., Lienau, P., Siemeister, G., Lücking, U., & Stegmann, C. M. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00074 · Cited by 83
Katewa, A., Wang, Y., Hackney, J. A., Huang, T., Suto, E., Ramamoorthi, N., Austin, C. D., Bremer, M. C. D., Chen, J. Z., Crawford, J. J., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.90111 · Cited by 73
Li, H., Lai, C., Pan, P., Yu, W., Liu, N., Bommineni, G. R., García–Díaz, M., Simmerling, C. L., & Tonge, P. J. (2014) · ACS Chemical Biology · doi:10.1021/cb400896g · Cited by 71
Self-citationKaur, P., Agarwal, S., & Datta, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005923 · Cited by 66
Spagnuolo, L. A., Eltschkner, S., Yu, W., Daryaee, F., Davoodi, S., Knudson, S. E., Allen, E. K. H., Merino, J., Pschibul, A., Moree, B., et al. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b11148 · Cited by 64
Self-citationSwinney, D. C., Beavis, P. A., Chuang, K., Zheng, Y., Lee, I., Gee, P., Deval, J., Rotstein, D. M., Dioszegi, M., Ravendran, P., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12683 · Cited by 61
Barkovich, K. J., Hariono, S., Garske, A. L., Zhang, J., Blair, J. A., Fan, Q., Shokat, K. M., Nicolaides, T. P., & Weiss, W. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0287 · Cited by 55
On-rate based optimization of structure–kinetic relationship – surfing the kinetic map
Schoop, A., & Dey, F. (2015) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2015.08.003 · Cited by 46
Vauquelin, G. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1067196 · Cited by 46
CNS Anticancer Drug Discovery and Development Conference White Paper
Levin, V. A., Tonge, P. J., Gallo, J. M., Birtwistle, M. R., Dar, A. C., Iavarone, A., Paddison, P. J., Heffron, T. P., Elmquist, W. F., Lachowicz, J. E., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov169 · Cited by 46
Self-citationLai, C., Li, H., Yu, W., Shah, S., Bommineni, G. R., Perrone, V., García–Díaz, M., Tonge, P. J., & Simmerling, C. L. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00284 · Cited by 42
Self-citationA quantitative mechanistic PK/PD model directly connects Btk target engagement and in vivo efficacy
Daryaee, F., Zhang, Z., Gogarty, K. R., Li, Y., Merino, J., Fisher, S. L., & Tonge, P. J. (2017) · Chemical Science · doi:10.1039/c6sc03306g · Cited by 42
Self-citationSeow, V., Lim, J., Cotterell, A. J., Yau, M., Xu, W., Lohman, R., Kok, W. M., Stoermer, M. J., Sweet, M. J., Reid, R. C., et al. (2016) · Scientific Reports · doi:10.1038/srep24575 · Cited by 40
Rudolph, J., Xiao, Y., Pardi, A., & Ahn, N. G. (2014) · Biochemistry · doi:10.1021/bi501101v · Cited by 39
Wang, X., Barbosa, J., Blomgren, P., Bremer, M. C. D., Chen, J., Crawford, J. J., Deng, W., Dong, L., Eigenbrot, C. W., Gallion, S., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00103 · Cited by 38
de Witte, W. E. A., Wong, Y. C., Nederpelt, I., Heitman, L. H., Danhof, M., van der Graaf, P. H., Gilissen, R., & de Lange, E. C. M. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1100163 · Cited by 35
Targeting Protein Kinases with Selective and Semipromiscuous Covalent Inhibitors
Miller, R. M., & Taunton, J. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-397918-6.00004-5 · Cited by 35
Glossop, P. A., Watson, C. A. L., Price, D. A., Bunnage, M. E., Middleton, D. S., Wood, A., James, K., Roberts, D. F., Strang, R. S., Yeadon, M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200884j · Cited by 34
The Added Value of Assessing Ligand–Receptor Binding Kinetics in Drug Discovery
Guo, D. M., Heitman, L. H., & IJzerman, A. P. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00273 · Cited by 33
Wentsch, H. K., Walter, N. M., Bührmann, M., Mayer‐Wrangowski, S. C., Rauh, D., Zaman, G. J. R., Willemsen‐Seegers, N., Buijsman, R. C., Henning, M., Dauch, D., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201701185 · Cited by 31
Daryaee, F., Chang, A. T., Schiebel, J., Lü, Y., Zhang, Z., Kapilashrami, K., Walker, S. G., Kisker, C., Sotriffer, C., Fisher, S. L., et al. (2016) · Chemical Science · doi:10.1039/c6sc01000h · Cited by 29
Self-citationVauquelin, G., Liefde, I. V., & Swinney, D. C. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13445 · Cited by 21
Yoshida, Y., Ozawa, T., Yao, T.-W., Wang, S., Brown, D., Parsa, A. T., Raizer, J. J., Cheng, S., Stegh, A. H., Mazar, A. P., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0306 · Cited by 17
Calbet, M., Andrés, M., Armengol, C., Bravo, M., Eichhorn, P., López, R., García‐González, V., Roberts, R. S., & Miralpeix, M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.014 · Cited by 14
(2009) · PubMed
Cited by
Why 90% of clinical drug development fails and how to improve it?
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.002 · Cited by 1,763
Targeted protein degradation: elements of PROTAC design
Paiva, S.-L., & Crews, C. M. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.02.022 · Cited by 576
Challenges and Opportunities in Cancer Drug Resistance
Ward, R. A., Fawell, S., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00383 · Cited by 445
Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis
Bosch, B., DeJesus, M. A., Poulton, N. C., Zhang, W., Engelhart, C. A., Zaveri, A., Lavalette, S., Ruecker, N., Trujillo, C., Wallach, J. B., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.033 · Cited by 316
Tang, Z., Chen, S.-H., & Chang, C.-E. A. (2020) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.9b01153 · Cited by 28
Metadata
- Authors
- Tonge, P. J.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-07-14
- Volume
- 9
- Issue
- 1
- Pages
- 29-39
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2664285537
- Cited by
- 287
- References
- 75
- FWCI
- 17.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.